Monoclonal antibodies against human cancer stem cells

Immunotherapy

Volumn 6, Issue 3, 2014, Pages 291-308

  Naujokat, Cord ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Center and Network for Targeted Oncology   (Germany)

Author keywords

cancer stem cells; cancer therapy; CD123; CD133; CD44; CD47; EpCAM; IGF receptor I; monoclonal antibody; Notch; Wnt

Indexed keywords

7G 3; ADECATUMUMAB; AVE 1642; B 6H 12; B 6H 122; BII 022; BORTEZOMIB; CATUMAXOMAB; CD123 ANTIBODY; CD44 ANTIBODY; CD47 ANTIBODY; CIXUTUMUMAB; CSL 360; CYTOSTATIC AGENT; DALOTUZUMAB; DEMCIZUMAB; EDRECOLOMAB; FIGITUMUMAB; GANITUMAB; INSULIN LIKE GROWTH FACTOR RECEPTOR 1 ANTIBODY; IRINOTECAN; MONOCLONAL ANTIBODY; MT 110; OMP 18R 5; OMP 21M 18; OMP 52M 51; PACLITAXEL; REGN 421; RG 7356; RO 5429083; SOLITOMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANTICTUMAB; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CANCER THERAPY; COLON CANCER; DRUG DOSE ESCALATION; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; MYELOMA; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR RECURRENCE; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG SCREENING; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899546885     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.4     Document Type: Review

References (127)

1. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: An evolving concept. Nat. Rev. Cancer 12, 133-143 (2012).
2. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012).
3. Valent P, Bonnet D, De Maria R et al. Cancer stem cell definitions and terminology: The devil is in the detail. Nat. Rev. Cancer 12, 767-775 (2012).
4. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66, 9339-9344 (2006).
5. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int. J. Biochem. Cell Biol. 44, 2144-2151 (2012).
6. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesemchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106, 13820-13825 (2009).
7. Tehranchi R, Woll PS, Anderson K et al. Persistant malignant stem cells in del(5q) myelodysplasia in remission. N. Engl. J. Med. 363, 1025-1037 (2010).
8. Gerber JM, Smith BD, Ngwang B et al. A clinically relevant population of leukemic CD34+CD38-cells in acute myeloid leukemia. Blood 119, 3571-3577 (2012).
9. Naujokat C, Laufer S. Targeting cancer stem cells with defined compounds and drugs. J. Cancer Res. Updates 2, 36-67 (2013).
10. Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
11. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672-679 (2008).
12. Bhatia R, Holtz M, Niu N et al. Persistance of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
13. Parmar A, Marz S, Rushton S et al. (2011) Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res. 71, 4696-4706 (2011).
14. Reim F, Dombrowski Y, Ritter C et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: Selective escape of CD44high/ CD24low/HER2low breast cancer stem cells. Cancer Res. 69, 8058-8066 (2009).
15. Cufi S, Corominas-Faja B, Vazquez-Martin A et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 3, 395-398 (2012).
16. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317-327 (2010).
17. Galluzzi L, Vacchelli E, Fridman WH et al. Trial watch: Monoclonal antobodies in cancer therapy. Oncoimmunology 1, 28-37 (2012).
18. Naujokat C. Targeting human cancer stem cells with monoclonal antibodies. Clin. Cell. Immunol. S5, 007 (2012).
19. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkins lymphoma. N. Engl. J. Med. 359, 613-626 (2008).
20. Fischer M, Yen WC, Kapoun AM et al. Anti-DLL4 inhibits and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 71, 1520-1525 (2011).
21. Gurney A, Axelrod F, Bond CJ et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl Acad. Sci. USA 109, 11717-11722 (2012).
22. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mod. Pathol. 52, 189-196 (1999).
23. Negi LM, Talegaonkar S, Jaggi M et al. Role of CD44 in tumour progression and strategies for targeting. J. Drug Target 20, 561-573 (2012).
24. Vira D, Basak SK, Veena MS et al. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 31, 733-751 (2012).
25. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2, 1167-1174 (2006).
26. Hertweck MK, Erdfelder F, Kreuzer KA. CD44 in hematological neoplasias. Ann. Hematol. 90, 493-508 (2011).
27. Ghosh SC, Neslihan Alpay S, Klostergaard J. CD44: A validated target for improved delivery of cancer therapeutics. Expert Opin. Ther. Targets 16, 635-650 (2012).
28. Charrad RS, Li Y, Delpech B et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat. Med. 5, 669-676 (1999).
29. Charrad RS, Gadhoum Z, Qi J et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 99, 290-299 (2002).
30. Gadhoum Z, Delaunay J, Maquarre E et al. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk. Lymphoma 45, 1501-1510 (2004).
31. Marangoni E, Lecomte N, Durant L et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancer xenografts. Br. J. Cancer 100, 918-922 (2009).
32. Idowu MO, Kmieciak M, Dumur C et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 43, 364-373 (2012).
33. Ricardo S, Vieira AF, Gerhard R et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64, 937-946 (2011).
34. Belitsos PC, Hildreth JE, August JT. Homotypic cell aggregation induced by anti-CD44(Pgp-1) monoclonal antibodies and related to CD44(Pgp-1) expression. J. Immunol. 144, 1661-1670 (1990).
35. Tang W, Hao X, He F, Li L, Xu L. Anti-CD44 antibody treatment inhibits pancreatic cancer metastasis and postradiotherapy recurrence. Cancer Res. 71(8 Suppl. 1), Abstract 565 (2011).
36. Masuko K, Okazaki S, Satoh M et al. antitumor effect against human cancer xenografts by a fully human monoclonal anibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS ONE 7, e29728 (2012).
37. Olsson E, Honeth G, Bendahl PO et al. CD44 isoforms are heterogenously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11, 418 (2011).
38. Perez A, Neskey DM, Wen J et al. Targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083. Cancer Res. 72(8 Suppl. 1), Abstract 2521 (2012).
39. Weigand S, Herting F, Maisel D et al. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist. Cancer Res. 72, 4329-4339 (2012).
40. Hama T, Yuza Y, Saito Y et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14, 900-908 (2009).
41. Zhang S, Wu CC, Fecteau JF et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc. Natl Acad. Sci. USA 110, 6127-6132 (2013).
42. Fedorchenko O, Stiefelhagen M, Peer-Zada AA et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 121, 4126-4136 (2013).
43. Kikushige Y, Ishikawa F, Miyamoto T et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246-259 (2011).
44. Open-label multicenter 2-Arm Phase I study of RO5429083 with dose escalation and extension cohorts, and imaging cohorts with RO5429083 and 89Zr-labeled RO5429083, in patients with metastatic and/or locally advanced, CD44-expressing, malignant solid tumors (2013). http://clinicaltrials.gov/show/ NCT01358903
45. Open-label, multicenter, dose escalation Phase 1a/b study of RO5429083, administered as intravenous infusion alone or in combination with cytarabine in patients with acute myelogenous leukemia (AML) (2013). http://clinicaltrials. gov/show/NCT01641250
46. Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225-232 (2012).
47. Jaiswal S, Jamieson CH, Pang WW et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
48. Willingham SB, Volkmer JP, Gentles AJ et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662-6667 (2012).
49. Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
50. Chan KS, Espinosa I, Chaoa A et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016-14021 (2009).
51. Chao MP, Tang C, Pachynski RK et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118, 4890-4901 (2011).
52. Chao MP, Alizadeh AA, Tang C et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374-1384 (2011).
53. Kim D, Wang J, Willingham SB et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26, 2538-2545 (2012).
54. Edris B, Weiskopf K, Volkmer AK et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl Acad. Sci. USA 109, 6656-6661 (2012).
55. Gholamin S, Mitra SS, Richard CE et al. Development of anti-CD47 therapy for pediatric brain tumors. Cancer Res. 73(8 Suppl. 1), Abstract 5281 (2013).
56. Tseng D, Volkmer JP, Willingham SB et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110, 11103-11108 (2013).
57. Sun Q, Woodcock JM, Rapoport A et al. Monoclonal antibody 7G3 recognizes the N-Terminal domain of the human interleukin-3 (IL-3) receptor α-chain and functions as a specific IL-3 receptor antagonist. Blood 87, 83-92 (1996).
58. Jordan CT, Upchurch D, Szilvassy SJ et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784 (2000).
59. Testa U, Riccioni R, Militi S et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100, 2980-2988 (2002).
60. Jin L, Lee EM, Ramshaw HS et al. Monoclonal antibodymediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cells 5, 31-42 (2009).
61. Vergez F, Green AS, Tamburini J et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemias: A Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 96, 1792-1798 (2011).
62. Leyton JV, Hu M, Gao C et al. Auger electron radioimmunotherapeutic agent specific for the CD123+/ CD131-phenotype of the leukemia stem cell population. J. Nucl. Med. 52, 1465-1473 (2011).
63. Roberts AW, He S, Ritchie D et al. A Phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. J. Clin. Oncol. 28(15 Suppl.), Abstract e13012 (2010).
64. A Phase 1 study of CSL362 (Anti-IL3Rα/Anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia in complete remission or complete remission with incomplete platelet recovery at high risk for early relapse (2012). http://clinicaltrials.gov/show/NCT01632852.
65. Kuo SR, Wong L, Liu JS. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng. Des. Sel. 25, 561-570 (2012).
66. Kügler M, Stein C, Kellner C et al. A recombinant trispecific single-chain Fv derivate directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br. J. Haematol. 150, 574-586 (2010).
67. Maetzel D, Denzel S, Mack B et al. Nuclear signalling by tumour-Associated antigen EpCAM. Nat. Cell Biol. 11, 162-171 (2009).
68. Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh. Migr. 6, 30-38 (2012).
69. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule (CD326) in cancer: A short review. Cancer Treat. Rev. 38, 68-75 (2012).
70. Brischwein K, Schlereth B, Guller B et al. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129-1143 (2006).
71. Haas C, Krinner E, Brischwein K et al. Mode of cytotoxic action of T-cell engaging BiTE antibody MT110. Immunobiology 214, 441-453 (2009).
72. Münz M, Herrmann I, Friedrich M et al. Functional importance of EpCAM for the activity of tumor-initiating cancer cells and their eradication by EpCAM/CD3-bispecific antibody MT110. Cancer Res. 71(8 Suppl. 1), Abstract 1790 (2011).
73. Herrmann I, Baeuerle PA, Friedrich M et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS ONE 5, e13474 (2010).
74. Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/ CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin. Cancer Res. 18, 465-474 (2012).
75. An open-label, multi-center dose escalation Phase I study to investigate the safety and tolerability of a continous infusion of the bispecific T-cell engager (BiTE) MT110 in locally advanced, recurrent or metastatic solid tumors which commonly express EpCAM and are not amenable to curative therapy (2008). http://clinicaltrials.gov/show/NCT00635596
76. Fiedler WM, Wolf M, Kebenko M et al. (2012) A Phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. J. Clin. Oncol. 30(15 Suppl.), Abstract 2504 (2012).
77. Chelius D, Ruf P, Gruber P et al. Structural and functional characterization of the trifunctional antibody catumaxomab. Mabs 2, 309-319 (2010).
78. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36, 458-467 (2010).
79. Schroeder P, Lindemann C, Dettmar K et al. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin. Transl. Oncol. 13, 889-898 (2011).
80. Atanackovic D, Reinhard H, Meyer S et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum. Vaccin. Immunother. doi:10.4161/ hv.26065 (2013) (Epub ahead of print).
81. Sebastian M, Kiewe P, Schuette W et al. Treatment of malignant pleural effusions with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x anti-CD3): Results of a Phase 1/2 study. J. Immunother. 32, 195-202 (2009).
82. Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial. Int. J. Cancer 127, 2209-2221 (2010).
83. Ströhlein MA, Lordick F, Rüttinger D et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: An open-label, multicenter, Phase I/II trial. Onkologie 34, 101-108 (2011).
84. Jäger M, Schoberth A, Ruf P et al. Immunomonitoring results of a Phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res. 72, 24-32 (2012).
85. Seimetz D. Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (removab). J. Cancer 2, 309-316 (2011).
86. Niedzwiecki D, Bertagnolli MM, Warren RS et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from the CALGB 9581. J. Clin. Oncol. 29, 3146-3152 (2011).
87. Schmidt M, Scheulen ME, Dittrich C et al. An open-label, randomized Phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann. Oncol. 21, 275-282 (2010).
88. Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012 (1997).
89. Grosse-Gehling P, Fargeas CA, Dittfeld C et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J. Pathol. 229, 355-378 (2013).
90. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J. Mol. Med. 86, 1025-1032 (2008).
91. Yu Y, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform of himan AC133 stem cell antigen. J. Biol. Chem. 277, 20711-20716 (2002).
92. Kemper K, Sprick MR, de Bree M et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 70, 719-729 (2010).
93. Waldron NN, Kaufman DS, Oh S et al. Targeting tumorinitiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenograft model of human head and neck cancer. Mol. Cancer Ther. 10, 1829-1839 (2011).
94. Huang J, Li C, Wang Y et al. Cytokine-induced killer (CIK) cells bound with antiCD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin. Immunol. 149, 156-168 (2013).
95. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res. 72, 3-12 (2012).
96. Moreau P, Cavallo F, Leleu X et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 25, 872-874 (2011).
97. Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat. Rev. 38, 292-302 (2012).
98. Dallas NA, Xia L, Gan F et al. Chemoresistant colorectal cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69, 1951-1957 (2009).
99. Hart LS, Dollof NG, Dicker DT et al. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10, 2331-2338 (2011).
100. Descamps G, Gomez-Bougie P, Venot C et al. A humanized anti-IGF-1R monoclonal antibody (AVE1642) enhances bortezomib-induced apoptosis in myeloma lacking CD45. Br. J. Cancer 100, 366-369 (2009).
101. Shao H, Huang Q, Liu ZJ. Targeting Notch signaling for cancer therapeutic intervention. Adv. Pharmacol. 65, 191-234 (2012).
102. Wang J, Sullenger BA, Rich JN. Notch signaling in cancer stem cells. Adv. Exp. Med. Biol. 727, 174-185 (2012).
103. Kuhnert F, Kirshner JR, Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc. Cell 3, 20 (2011).
104. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177 (2009).
105. Yen WC, Fischer MM, Hynes M et al. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin. Cancer Res. 18, 5374-5386 (2012).
106. Beviglia L, Yeung P, Fischer M et al. Anti-DLL4 treatment inhibits melanoma tumor growth, recurrence, metastases, and reduces frequency of cancer stem cells in a clinically relevant tumor model in NOD/SCID mice. Cancer Res. 71(8 Suppl. 1), Abstract 2834 (2011).
107. Yen WC, Fischer MM, Shah J et al. Anti-DLL (demcizumab) inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts. Cancer Res. 73(8 Suppl. 1), Abstract 3725 (2013).
108. Breviglia L, Yeung P, Fischer M et al. Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors, Cancer Res. 72(8 Suppl. 1), Abstract LB-196 (2012).
109. Yen WC, Fischer M, Lewicki J, Gurney A, Hoey T. Targeting cancer stem cells by an anti-DLL4 antibody inhibits epithelial-To-mesenchymal transition, delays tumor recurrence and overcomes drug resistance in breast and pancreatic cancer. Cancer Res. 72(8 Suppl. 1), Abstract 3357 (2012).
110. A Phase 1b study of FOLFIRI plus OMP-12M18 as 1st or 2nd-line treatment in subjects with metastatic colorectal cancer (2010). http://clinicaltrials.gov/ show/NCT01189942
111. A Phase 1b study of gemcitabine plus OMP-21M18 as 1st-line treatment in subjects with locally advanced or metastatic pancreatic cancer (2010). http://clinicaltrials.gov/show/NCT01189929
112. A Phase 1b study of carboplatin and pemetrexed plus OMP-21M18 as 1st-line treatment in subjects with non-squamous non-small cell lung cancer (2010). http://clinicaltrials.gov/show/NCT01189968
113. Noguera-Troise I, Daly C, Papadopoulos NJ et al. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 444, 1032-1037 (2006).
114. A multiple-Ascending-dose study of the safety and tolerability of REGN421(SAR153192) in patients with advanced solid malignancies. http://clinicaltrials.gov/show/NCT00871559
115. Jimeno A, LoRusso P, Strother RM et al. Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors. J. Clin. Oncol. 31(15 Suppl.), Abstract 2502 (2013).
116. Cancilla B, Cain J, Wang M et al. Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types. Cancer Res. 73(8 Suppl. 1), Abstract 3728 (2013).
117. A Phase 1 dose escalation study of OMP-52M51 in subjects with solid tumors (2013). http://clinicaltrials.gov/show/NCT01778439
118. A Phase 1 dose escalation study of OMP-52M51 in subjects with lymphoid malignancies (2013). http://clinicaltrials.gov/show/NCT01703572
119. Ueno K, Hirata H, Hinoda Y, Dahiya R. Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int. J. Cancer 132, 1731-1740 (2013).
120. Yen WC, Fischer M, Lewicki J, Gurney A, Hoey T. (2011) Targeting cancer stem cells by a novel anti-frizzled antibody inhibits pancreatic tumor growth and induces differentiation. Cancer Res. 71(8 Suppl. 1), Abstract 973 (2011).
121. Lewicki J, Axelrod F, Beviglia L et al. Development of a novel Wnt pathway antagonist antibody, OMP-18R5, that reduces tumor initiating cell frequency in breast cancer. Cancer Res. 72(8 Suppl. 1), Abstract 3356 (2012).
122. A Phase 1 dose escalation study of OMP-18R5 in subjects with solid tumors (2011). http://clinicaltrials.gov/show/NCT01345201
123. Smith DC, Rosen LS, Chugh R et al. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting WNT pathway in a Phase I study for patients with advanced solid tumors. J. Clin. Oncol. 31(15 Suppl.), Abstract 2540 (2013).
124. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
125. Ithimakin S, Day KC, Malik F et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Inplications for efficacy of adjuvant trastuzumab. Cancer Res. 73, 1635-1646 (2013).
126. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883-887 (2011).
127. Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: Are they ready for the clinic? Eur. J. Cancer 48, 2104-2116 (2012).